Conférence de concertation sur la coqueluche
[Table des Matières]
|
|
RÉFÉRENCES
- CDC. Pertussis - United States, 1997-2000. MMWR 2002;51:76-6.
- Wortis N, Strebel PM, Wharton M et coll.
B. pertussis deaths: report of 23 cases in the United States,
1992 and 1993. Pediatrics 1996;97:607-12.
- Heininger U, Stehr K, Schmidt-Schläpfer G et coll. Bordetella
pertussis infections and sudden unexpected deaths in children.
Eur J Pediatr 1996;155:551-53.
- Jenkinson D. Natural course of 500 consecutive cases of whooping
cough: a general practice population.Br Med J 1995;310:299-302.
- Jenkinson D. Duration of effectiveness of pertussis vaccine: evidence
from a 10-year community study. Br Med J 1988;296:612-14.
- Yih WK, Lett SM, des Vignes FN et coll. The increasing incidence
of pertussis in Massachusetts adolescents and adults, 1989-1998.
J Infect Dis 2000;182:1409-16.
- Heininger U, Schmidt-Schläpfer G, Cherry JD et coll. Clinical
validation of a polymerase chain reaction assay for the diagnosis of
pertussis by comparison with serology, culture, and symptoms during
a large pertussis vaccine efficacy trial. Pediatrics 2000;105:31.
- Senzilet LD, Halperin SA, Spika JS et coll. et le Groupe de travail
sur la coqueluche du Système de surveillance par unité de
santé sentinelle. Pertussis is a frequent cause of prolonged
cough illness in adults and adolescents. Clin Infect Dis 2001;32:1691-97.
- Decker MD, Edwards KM. The multicenter acellular pertussis trial:
an overview. J Infect Dis 1996;174(suppl 3):S270-5.
- Grimprel E, Guiso N, Bégué P. New aspects of pertussis
in France, 26 years after generalized pertussis vaccination. Biologicals
1993;21:5-6.
- Baron S, Njamkep E, Grimprel E et coll. Epidemiology of pertussis
in France, 1993-1994. Pediatr Infect Dis J 1997;17:412-18.
- Gilbert S, Njamkepo E, Parent du Châtelet I et coll. Evidence
of Bordetella pertussis with persistent cough in a French area with
very high whole-cell vaccine coverage. J Infect Dis 2002.186 (sous
presse).
- Miller E, Fleming DM, Ashworth LAE et coll. Serological evidence
of pertussis in patients presenting with cough in general practice in
Birmingham. Commun Dis Public Health 2000;3:132-4.
- Crowcroft NS, Spicer L, Tzivra O et coll. Pertussis is under-estimated
in infants admitted to paediatric intensive care units and wards in
London (résumé). Proceedings of the 19th
Annual Meeting of the European Society for Paediatric Infectious Diseases,
Istanbul, Turkey, 2001.
- Morris A, McIntyre P, Elliot E et coll. Hospitalised pertussis
in Australian infants in 2001(résumé). Royal Australian
College of Physicians Annual Scientific Meeting, Brisbane, Australia,
May 2002.
- Thomas P, McInytre P, Jalaludin B. Survey of pertussis morbidity
in adults in western Sydney. Med J Aust 2000;173:74-76.
- Poynton M, Irwig L, Hanlon M et coll. Serological diagnosis of
pertussis: evaluation of IgA against whole cell and specific Bordetella
pertussis antigens as markers of recent infection. Epidemiol Infect
2002 (in press).
- Zepp F, Knuf M, Habermehl P et coll. Pertussis-specific cell-mediated
immunity in infants after vaccination with a tricomponent acellular
pertussis vaccine. Infect Immun 1996;64:4078-84
- Zepp F, Knuf M, Habermehl P et coll. Cell-mediated immunity after
pertussis vaccination and after natural infection. Dev Biol Stand
1997;89:307-14.
- Tinnion ON, Hanlon M. Acellular vaccines for preventing whooping
cough in children. Cochrane Database Syst Rev 2000;(2):CD001478.
- Taranger J, Trollfors B, Bergfors E et coll. Immunologic and epidemiologic
experience of vaccination with a monocomponent pertussis toxoid vaccine.
Pediatrics 2001;108 .
URL : http://www.pediatrics.org/cgi/content/full/108/6/e115
- Salmaso S, Mastrantonio P, Tozzi AE et coll. Sustained efficacy
during first 6 years of life of 3-component acellular pertussis
vaccines administered in infancy: the Italian experience. Pediatrics
2001;108(5):e81.
- Lugauer S, Heininger U, Cherry JD et coll. Long-term clinical effectiveness
of an acellular pertussis component vaccine and a whole cell component
vaccine. Eur J Pediatr 2002;161:142-6.
- Halperin SA, Eastwood BJ, Barreto L et coll. Adverse reactions
and antibody response to four doses of acellular or whole cell pertussis
vaccine combined with diphtheria and tetanus toxoids in the first 19
months of life. Vaccine 1996;14:767-72.
- Halperin S, Scheifele D, Barreto L et coll. Comparison of a fifth
dose of a five-component acellular or a whole cell pertussis vaccine
in children four to six years of age. Pediatr Infect Dis J 1999;18:772-79.
- Pichichero ME, Edwards KM, Anderson EL et coll. Safety and immunogenicity
of six acellular pertussis vaccines and one whole-cell pertussis vaccine
given as a fifth dose in four- to six-year old children. Pediatrics
2000;105:e11.
- Schmitt HJ, Beutel K, Schuind A. Reactogenicity and immunogenicity
of a booster dose of a combined diphtheria, tetanus, and tricomponent
acellular pertussis vaccine at 14 to 28 months of age. J Pediatr
1997;130:616-23.
- Halperin SA, Smith B, Russell M et coll. An adult formulation of
a five-component acellular pertussis vaccine combined with diphtheria
and tetanus toxoids is safe and immunogenic in adolescents and adults.
Vaccine 2000;18:1312-19.
- Hemels MEH et coll. Economic evaluation of an extended acellular
pertussis programme for adolescents in Ontario, Canada. Devant être
publié.
- Comité consultatif national de l'immunisation, Comité
consultatif de l'épidémiologie, Société canadianne
de pédiatrie. Déclaration concernant la prise en charge des
personnes exposées à la coqueluche et la lutte contre les
épidémies de coqueluche. RMTC 1994;20(22):193-200.
- Comité consultatif national de l'immunisation. Guide
canadien d'immunisation, 4e éd. Ottawa: Association
médicale canadienne, 1998.
- Halperin S, Bortolussi R, Langley JM et coll. Seven days of erythromycin
is as effective as fourteen days for the treatment of Bordetella pertussis
infections. Pediatrics 1997;100:65-71.
- Lebel MH, Mehra S. Efficacy and safety of clarithromycin versus
erythromycin for the treatment of pertussis: a prospective, randomized,
single blind trial. Pediatr Infect Dis J 2001;20:1149-54.
- Halperin S, Bortolussi R, Langley JM et coll. A randomized, placebo-controlled
trial of erythromycin estolate chemoprophylaxis for household contacts
of children with culture-positive Bordetella pertussis infection.
Pediatrics 1999;104 .
URL : http://www.pediatrics.org/cgi/content/full/104/4/e42
- De Serres G, Boulianne N, Duval B. Field effectiveness of erythromycin
prophylaxis to prevent pertussis within families. Pediatr Infect
Dis J 1995;14:969-975.
- Deeks S, De Serres G, Boulianne N et coll. Failure of physicians
to consider the diagnosis of pertussis in children. Clin Infect
Dis 1999;28:840-46.
[Précédent] [Table
des matières] [Prochaine]
|